Manchester United Stock Higher After Dramatic Comeback

Manchester United advanced to the quarterfinals of the UEFA Champions League

by Patrick Martin

Published on Mar 7, 2019 at 2:45 PM

The Dow is lower again today, heading toward its fourth straight loss. Among stocks making notable moves today, discount retailer Five Below Inc (NASDAQ:FIVE) and soccer franchise Manchester United PLC (NYSE:MANU) are climbing, while pharma company Aptinyx Inc (NASDAQ:APTX) is struggling. Here's a quick look at what's got the shares of FIVE, MANU, and APTX moving today.

Oppenheimer Bullish on Five Below

Five Below stock is up 2.2% to trade at $117.37, after Oppenheimer initiated coverage on the discount retailer with an "outperform" rating and $140 price target. The brokerage firm called FIVE "one of the few remaining retail growth stories," and hailed its "unique and defensible" small-store format. FIVE has shed 7.8% in the past month, but the selling appears to have been contained by its 160-day moving average. 

An unwinding of short interest could keep the wind at the equity's back. Short interest fell by 15% in the last two reporting periods, yet the 3.24 million shares still sold short represents a healthy 6% of FIVE's total available float, and more than a week's worth of pent-up buying power, at its average pace of trading. 

Champions League Comeback Has MANU In Form

Yesterday, Manchester United became the first soccer club to overturn a 2-0 deficit in the UEFA Champions League, beating Paris Saint-Germain on away goals in a last-minute 3-1 victory. United advances to the quarterfinals of the UCL. In reaction, MANU is up 2.4% to trade at $20.17, climbing above its year-over-year breakeven point. Since breaching $17 in early December, Manchester United stock has added nearly 20%.

An analyst at Gabelli weighed in on the club, calling it a "stunningly positive and it is only going to help sponsors." Overall, though, analysts are skewed on the iconic club. Half of the brokerages rate MANU a "strong buy," while the other half rate it a tepid "hold." 

Failed Depression Drug Digs in to APTX

Aptinyx stock is down 10.5% to trade at $4.66, and earlier fell to a record low of $4.50. The stock's struggles today are linked to Allergan (AGN) and its experimental depression treatment that failed three-late stage studies. Aptinyx co-developed, and later sold the treatment the Allergan. After consolidating below $6 all year, APTX has now shed 73% from its June 21 opening price of $17.40. 

A shift in analyst sentiment could be on the way. Of the five brokerages covering APTX, four rate it a "buy" or better, with zero "sells" on the books. Plus, the security's consensus 12-month price target of $19.33 is a 314% premium to its current perch.

a schaeffer's exclusive


Heat up your summer trading with this FREE insider report!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

The Future of Marijuana is in the "Priceline of Pot"
Click to continue to advertiser's site.
IPO Recap: Chewy Surges, Revolve Pushes Higher
A quick look at recent IPO news and moves
Options Traders are Going Wild for These 2 Stocks
Ashford Hospitality is eyeing its worst day in nearly eight years
The Future of Marijuana is in the "Priceline of Pot"
Click to continue to advertiser's site.